Midori Ogasawara, So Okubo, Kohei Shinmura, Hitomi Nakayama, Aki Sakurai, Chisako Ito et al. Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma. // Annals of Hematology. – 2025. – DOI: 10.1007/s00277-025-06187-3. – URL: https://doi.org/10.1007/s00277-025-06187-3
Midori Ogasawara, So Okubo, Kohei Shinmura, Hitomi Nakayama, Aki Sakurai, Chisako Ito, Yoshinobu Aisa, & Tomonori Nakazato (2025). Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-025-06187-3
Midori Ogasawara, et al. “Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma.” Annals of Hematology, 2025. doi:10.1007/s00277-025-06187-3.
@article{Ogasawara2025,
title = {Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma},
author = {Ogasawara, Midori and Okubo, So and Shinmura, Kohei and Nakayama, Hitomi and Sakurai, Aki and Ito, Chisako and Aisa, Yoshinobu and Nakazato, Tomonori},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06187-3},
url = {https://doi.org/10.1007/s00277-025-06187-3}
}